Where do the recommendations in the report come from?

The recommendations in Inagene’s report are taken directly from published pharmacogenetic recommendations (publicly available) from several well-recognized, government-funded governing bodies that have been established over the past two decades in the USA, Europe, and Asia. 

Research over the last three decades has generated an overwhelming amount of evidence that genetic variation plays a major role in how individuals respond to different drugs. These include the Food and Drug Administration (FDA), Clinical Pharmacogenetics Implementation Consortium (CPIC), the Pharmacogenomics Knowledge Base (PharmGKB), EMA (European Medicines Agency), Health Canada, and the Dutch Pharmacogenetics Working Group (DPWG). 

If you are interested in learning more about these recommendations, your report will have direct links to our sources where you can learn more about the validated science.